Fairvalue-Calculator Fairvalue-Calculator
EN DE

Borregaard ASA (BRG) Fair Value & Analysis

Basic Materials · NO · Market cap 14.2B NOK

Pricekr 144.20
Fair Valuekr 95.67
Upside-33.7%
Quality95/100
Evidence: High Range kr 54.01 – kr 132.22

Analysis

Borregaard ASA (BRG) currently trades at kr 144.20, while our model-based Fair Value estimate is kr 95.67 — implying the stock looks roughly 33.7% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment develops, produces, and sells biopolymers and biovanillin derived from lignin for agrochemicals, batteries, industrial binders, and construction, as well as to flavor and fragrance companies, and food and beverage industry. Its BioMaterials segment develops, produces, and sells speciality cellulose used as a raw material in the production of cellulose ethers, cellulose acetate, and other specialty products, as well as cellulose fibrils for industrial applications. The Fine Chemicals segment supplies fine chemical intermediates for contrast agents and advanced bioethanol. The company was incorporated in 2012 and is headquartered in Sarpsborg, Norway.

Open the full interactive analysis →

Similar stocks

Linde plc (LIN) -57% L'Air Liquide S.A (AIQUY) -59% Air Products and Chemicals, Inc (A1PD34) -70% Intercontinental Exchange, Inc (I1CE34) -15% Wanhua Chemical Group (600309) -31% Asian Paints Limited (ASIANPAINT) -76%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.